|Bid||0.0000 x 800|
|Ask||6.5800 x 1200|
|Day's Range||4.8200 - 5.0500|
|52 Week Range||4.7100 - 54.5400|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Bain Capital has unveiled an approximately $1.1 billion life sciences fund, its second targeting the fast-growing industry, a spokesperson for the private equity giant said Wednesday. As a private equity firm, it generally makes later-stage investments than many of the venture capital firms that target the biotech sector.
Biotech giant Vertex Pharmaceuticals announced plans Thursday to acquire a Cambridge-based preclinical gene editing startup, giving a run for the money to fellow Cambridge drugmaker Sarepta Therapeutics and others developers of drugs for Duchenne muscular dystrophy.
An analyst suggested investors look at Sarepta Therapeutics' array of gene therapies on Tuesday after rival Solid Biosciences reported its key gene therapy caused side effects in a patient.
(Bloomberg Opinion) -- It’s easy to get excited about gene therapies, a group of new medicines that have the potential to cure diseases in one treatment. The saga of Solid Biosciences Inc. is a reminder that tweaking genes isn’t a trivial task. These therapies are full of promise, but they’re not entirely there yet.
The gene therapy developer appears to be struggling to find a safe and effective dose of its experimental Duchenne muscular dystrophy treatment.
Solid Biosciences said in the earnings release that, among the two patients randomized in the second cohort of the Phase 1/2 study dubbed IGNITE, one was dosed with 2E14 vg/kg of its DMD gene therapy candidate and another was added to the control group. The patient in the treatment arm experienced a transient decline in platelet count, considered a serious adverse event, or SAE, related to the study. The patient also experienced a transient elevation of transaminases as well as a transient increase in bilirubin, higher than two times the upper limit of normal, which was reported as an SAE related to the study, the company said.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.
Bain Capital is in the process of raising money for a second life sciences fund, less than two years after it amassed $720 million for its inaugural fund targeting the fast-growing sector. Bain revealed the new fund in a securities filing last week. The filing does not say how much the Boston-based private equity firm is hoping to raise.
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
With one drug already being considered by the FDA, Sarepta Therapeutics Inc. is now planning to submit another drug for Duchenne muscular dystrophy to the FDA this year.
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
Roche Holdings AG Basel ADR (OTC: RHHBY )'s announcement regarding an agreement to acquire gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE ) has sparked a rally in the latter's shares. The Analysts ...
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
Why Solid Biosciences Stock Nosedived 67.82% YesterdayStock price movements On February 7, Solid Biosciences (SLDB) closed at $7.19, 67.82% lower than its previous closing price, 5.27% higher than its 52-week low of $6.83, and 86.89% below its
Solid Biosciences crashed Thursday after its experimental gene therapy disappointed in a study of Duchenne muscular dystrophy patients. Sarepta Therapeutics, a rival, saw shares pop.
Cambridge biotech Solid Biosciences' stock dropped more than 70 percent Thursday after its Duchenne muscular dystrophy drug failed to come close to the effectiveness of its competitor in early tests.